BUDGET IMPACT OF SELINEXOR COMBINATION REGIMENS IN PREVIOUSLY TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Carter, J. A. [1 ]
Ijioma, S. [2 ]
Ray, D. [3 ]
机构：
[1] OPEN Hlth, Bethesda, MD USA
[2] Karyopharm Therapeut Inc, Marietta, GA USA
[3] Karyopharm Therapeut Inc, Newton, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE403
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [21] Selinexor, bortezomib, and dexamethasone in patients with previously treated multiple myeloma: updated results of BOSTON trial by prior therapies
    Mateos, Maria-Victoria
    Engelhardt, Monika
    Leleu, Xavier
    Gironella Mesa, Mercedes
    Cavo, Michele
    Dimopoulos, Meletios
    Bianco, Martina
    Merlo, Giovanni Marino
    La Porte, Charles
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S201 - S201
  • [22] Efficacy of Selinexor Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review
    Khalid, Farhan
    Hashmi, Mydah Sajid
    Tayyeb, Muhammad
    Jaan, Ali
    Ahmed, Zahoor
    Dar, Abdul Jabbar
    Aamir, Sobia
    Khurshid, Qasim
    Kashyap, Richi
    Khan, Israr
    Rehman, Saif Ur
    Ehsan, Hamid
    Anwer, Faiz
    BLOOD, 2020, 136
  • [23] COST-EFFECTIVENESS OF ONCE WEEKLY SELINEXOR-BORTEZOMIB-DEXAMETHASONE (XVD) IN PREVIOUSLY TREATED MULTIPLE MYELOMA (MM)
    Dolph, M.
    Tremblay, G.
    Leong, H.
    VALUE IN HEALTH, 2021, 24 : S34 - S34
  • [24] Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study
    Zhai, Yingying
    Yan, Lingzhi
    Jin, Song
    Shang, Jingjing
    Shi, Xiaolan
    Yao, Weiqin
    Yan, Zhi
    Yan, Shuang
    Wu, De-pei
    Fu, Chengcheng
    BLOOD, 2023, 142
  • [25] Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
    Auner, Holger W.
    Gavriatopoulou, Maria
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Dimopoulos, Meletios A.
    Kriachok, Iryna
    Pylypenko, Halyna
    Leleu, Xavier
    Doronin, Vadim
    Usenko, Ganna
    Hajek, Roman
    Benjamin, Reuben
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don Ambrose
    Quach, Hang
    Jagannath, Sundar
    Moreau, Phillipe
    Levy, Moshe
    Badros, Ashraf
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Facon, Thierry
    Victoria Mateos, Maria
    Cavo, Michele
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 708 - 718
  • [26] Selinexor, bortezomib, and dexamethasone in patients with previously treated multiple myeloma (MM): updated results of BOSTON trial by prior therapies
    Mateos, M. -V.
    Engelhardt, M.
    Leleu, X.
    Mesa, M. G.
    Cavo, M.
    Dimopoulos, M.
    Bianco, M.
    Merlo, G. M.
    la Porte, C.
    Moreau, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 176 - 176
  • [27] Selinexor for the treatment of multiple myeloma
    Podar, Klaus
    Shah, Jatin
    Chari, Ajai
    Richardson, Paul G.
    Jagannath, Sundar
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (04) : 399 - 408
  • [28] Selinexor Approved for Multiple Myeloma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 498 - 498
  • [29] Responses to selinexor in multiple myeloma
    Diana Romero
    Nature Reviews Clinical Oncology, 2019, 16 : 661 - 661
  • [30] Responses to selinexor in multiple myeloma
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (11) : 661 - 661
12345